News & Updates

In early to mid-pregnancy, low or excessively high maternal serum folate levels carry a heightened risk of congenital heart disease (CHD) in the offspring, as shown in a study.

New drug applications approved by US FDA as of 1-15 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Children with eosinophilic esophagitis (EoE) with a period of histologic disease control and diagnosed at younger ages appear to have reduced odds of developing esophageal strictures, according to a cohort study with >10 years of follow-up.

New drug applications approved by US FDA as of 16-30 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In the treatment of obesity in adolescents, the incidence of suicidal ideation or attempts appears to be lower among those receiving a glucagon-like peptide 1 receptor agonist (GLP1-RA) than among those undergoing lifestyle intervention alone, according to a retrospective study.

A single dose of oxybutynin before urologic surgery helps children with an indwelling urinary drain to reduce their use of opioid after the procedure, a study has shown.

A prospective cohort study has linked prenatal use of aspirin to better neurocognitive development in offspring.

Treatment with upadacitinib demonstrated superior efficacy in achieving near-complete skin clearance and little to no itch at 16 weeks compared with dupilumab among adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to the LEVEL UP study presented at EADV 2024.

As-needed application of ruxolitinib cream, a topically administered selective Janus kinase 1/2 inhibitor, resulted in long-term safety and disease control in children aged 2–11 years with mild-to-moderate atopic dermatitis (AD), according to updated results of the phase III TRuE-AD3 trial presented at EADV 2024.